Overnight Trade Opportunity Next Week?!
I'm looking at a BIG Overnight Trade opportunity next week. So big, I'm going to give it to you FREE! In fact, for the week of June 26th - 30th you can join our FREE Open House! You can get ALL our Overnight Trade recommendations, plus ALL of our research and other real-time recommendations!
pixel

NASDAQ:ALBO - Albireo Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $75.57
  • Forecasted Upside: 145.36 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$30.80
▼ -0.95 (-2.99%)

This chart shows the closing price for ALBO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Albireo Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALBO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALBO

Analyst Price Target is $75.57
▲ +145.36% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Albireo Pharma in the last 3 months. The average price target is $75.57, with a high forecast of $82.00 and a low forecast of $65.00. The average price target represents a 145.36% upside from the last price of $30.80.

This chart shows the closing price for ALBO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
Overnight Trade Opportunity Next Week?!
I'm looking at a BIG Overnight Trade opportunity next week. So big, I'm going to give it to you FREE! In fact, for the week of June 26th - 30th you can join our FREE Open House! You can get ALL our Overnight Trade recommendations, plus ALL of our research and other real-time recommendations!
pixel

Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in Albireo Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/29/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/22/2021Robert W. BairdBoost Price TargetOutperform$67.00 ➝ $72.00High
7/21/2021WedbushBoost Price TargetOutperform$73.00 ➝ $82.00High
7/21/2021HC WainwrightBoost Price TargetBuy$76.00 ➝ $79.00Low
3/26/2021Jefferies Financial GroupBoost Price TargetPositive ➝ Buy$79.00 ➝ $82.00High
3/1/2021Piper SandlerBoost Price TargetOverweight$68.00 ➝ $81.00Low
3/1/2021Robert W. BairdReiterated RatingBuy$67.00Low
12/18/2020HC WainwrightBoost Price TargetBuy$67.00 ➝ $75.00High
11/19/2020WedbushReiterated RatingBuy$66.00Low
9/18/2020WedbushReiterated RatingBuy$62.00High
9/10/2020CowenBoost Price Target$39.00 ➝ $65.00Medium
9/8/2020Jefferies Financial GroupBoost Price TargetPositive ➝ Buy$50.00 ➝ $79.00High
9/8/2020Needham & Company LLCBoost Price TargetBuy$50.00 ➝ $68.00High
9/8/2020HC WainwrightBoost Price TargetPositive ➝ Buy$50.00 ➝ $67.00High
9/8/2020Piper SandlerBoost Price TargetOverweight$45.00 ➝ $81.00High
8/19/2020HC WainwrightLower Price TargetBuy$64.00 ➝ $50.00High
8/10/2020William BlairReiterated RatingBuyLow
7/30/2020Piper SandlerInitiated CoverageOverweight$45.00High
7/28/2020Needham & Company LLCReiterated RatingBuy$50.00Medium
7/27/2020CowenReiterated RatingOutperform$39.00Medium
7/16/2020HC WainwrightBoost Price TargetBuy$62.00 ➝ $64.00Medium
6/24/2020Robert W. BairdInitiated CoverageOutperform$52.00High
6/17/2020WedbushReiterated RatingOutperformHigh
6/16/2020Needham & Company LLCInitiated CoverageBuy$50.00Medium
6/14/2020HC WainwrightReiterated RatingBuy$62.00Medium
5/11/2020WedbushReiterated RatingBuy$60.00High
5/7/2020Needham & Company LLCInitiated CoverageBuy$50.00High
4/5/2020HC WainwrightReiterated RatingBuy$62.00High
3/5/2020CowenReiterated RatingBuy$39.00Low
3/3/2020HC WainwrightReiterated RatingBuy$62.00High
3/3/2020WedbushLower Price TargetOutperform$69.00 ➝ $60.00High
1/30/2020HC WainwrightReiterated RatingBuy$62.00High
11/6/2019CowenReiterated RatingBuy$39.00Low
11/6/2019WedbushReiterated RatingBuy$69.00Low
8/11/2019HC WainwrightReiterated RatingBuy$62.00Medium
8/9/2019WedbushReiterated RatingOutperform$69.00High
7/15/2019William BlairReiterated RatingBuyLow
7/11/2019WedbushSet Price TargetBuy$69.00Medium
7/10/2019HC WainwrightReiterated RatingBuy$62.00High
5/23/2019WedbushSet Price TargetBuy$69.00Low
5/9/2019William BlairReiterated RatingOutperformHigh
4/17/2019CowenReiterated RatingBuyHigh
3/10/2019WedbushSet Price TargetBuy$69.00High
2/28/2019HC WainwrightInitiated CoverageBuy ➝ Buy$62.00High
1/25/2019WedbushReiterated RatingBuy$69.00Low
11/14/2018CowenReiterated RatingBuyMedium
11/13/2018Needham & Company LLCReiterated RatingBuy$50.00Low
10/17/2018WedbushReiterated RatingBuy$69.00Medium
8/8/2018CowenReiterated RatingBuyHigh
8/7/2018WedbushReiterated RatingOutperform$69.00Low
7/16/2018WedbushReiterated RatingOutperformLow
6/12/2018WedbushReiterated RatingOutperform$69.00Medium
4/20/2018WedbushReiterated RatingOutperform$63.00Low
4/20/2018Jefferies Financial GroupInitiated CoverageBuy$50.00High
3/28/2018WedbushReiterated RatingOutperform$63.00Medium
3/15/2018Needham & Company LLCInitiated CoverageBuy$50.00High
2/2/2018Needham & Company LLCBoost Price TargetBuy$50.00Low
1/19/2018WedbushReiterated RatingBuyLow
1/3/2018WedbushReiterated RatingBuyHigh
11/17/2017CowenReiterated RatingBuyN/A
11/15/2017Roth CapitalInitiated CoverageBuy ➝ Buy$92.00N/A
10/26/2017Needham & Company LLCReiterated RatingBuyN/A
9/11/2017WedbushReiterated RatingOutperform$58.00Low
8/16/2017CowenInitiated CoverageOutperformHigh
7/18/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$35.00High
6/30/2017WedbushInitiated CoverageOutperformHigh
2/16/2017LADENBURG THALM/SH SHInitiated CoverageBuyN/A
1/25/2017William BlairInitiated CoverageOutperformN/A
(Data available from 7/24/2016 forward)
Albireo Pharma logo
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis. It has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. The company is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $30.80
Low: $30.37
High: $32.05

50 Day Range

MA: $33.61
Low: $30.11
High: $36.87

52 Week Range

Now: $30.80
Low: $22.78
High: $49.00

Volume

395,081 shs

Average Volume

334,676 shs

Market Capitalization

$591.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.55

Frequently Asked Questions

What sell-side analysts currently cover shares of Albireo Pharma?

The following Wall Street analysts have issued reports on Albireo Pharma in the last year: Cowen Inc, HC Wainwright, Jefferies Financial Group Inc., Needham & Company LLC, Piper Sandler, Robert W. Baird, Wedbush, William Blair, and Zacks Investment Research.
View the latest analyst ratings for ALBO.

What is the current price target for Albireo Pharma?

7 Wall Street analysts have set twelve-month price targets for Albireo Pharma in the last year. Their average twelve-month price target is $75.57, suggesting a possible upside of 145.4%. Jefferies Financial Group Inc. has the highest price target set, predicting ALBO will reach $82.00 in the next twelve months. Cowen Inc has the lowest price target set, forecasting a price of $65.00 for Albireo Pharma in the next year.
View the latest price targets for ALBO.

What is the current consensus analyst rating for Albireo Pharma?

Albireo Pharma currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALBO will outperform the market and that investors should add to their positions of Albireo Pharma.
View the latest ratings for ALBO.

What other companies compete with Albireo Pharma?

How do I contact Albireo Pharma's investor relations team?

Albireo Pharma's physical mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company's listed phone number is (857) 254-5555 and its investor relations email address is [email protected] The official website for Albireo Pharma is www.albireopharma.com.

Overnight Trade Opportunity Next Week?!
I'm looking at a BIG Overnight Trade opportunity next week. So big, I'm going to give it to you FREE! In fact, for the week of June 26th - 30th you can join our FREE Open House! You can get ALL our Overnight Trade recommendations, plus ALL of our research and other real-time recommendations!
pixel